Sofracort · DIN 02224623 · 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol
General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Sofracort · DIN 02224623
Manufacturer: Sanofi Aventis Pharma; listing date 2001-10-11
Health Canada: Marketed since 2024-07-30 · brand SOFRACORT · ATC S03CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Drops · route Otic, Ophthalmic · ingredients FRAMYCETIN SULFATE 5 MG/ML, DEXAMETHASONE (DEXAMETHASONE SODIUM METASULPHOBENZOATE) 0.5 MG/ML, GRAMICIDIN 0.05 MG/ML · company Cheplapharm arzneimittel gmbh · schedule Prescription
Sofracort: Formulary list price $2.2212/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.2212 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37363 · Verify on the e-Formulary ↗ (DIN 02224623)
Source record
DIN 02224623: Sofracort
Raw flags: sec3=Y
Item: 520404012; group id 577; item number 1532; lccId None; manufacturer id SAV
Source form: Oph/Ot Sol; strength: 5mg & 50mcg & 0.5mg/mL
Recorded listing: General benefit
Source prices (unrounded): $2.2212; ministry $2.2212
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02224623
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37363
Therapeutic Notes (formulary)
The risk of ototoxicity with topical aminoglycoside may increase with prolonged therapy. Topical use of antibiotics increases the likelihood of development of bacterial resistance, especially with prolonged use, sometimes rendering the systemic use of this antibiotic class useless in these patients.
Shortage status: not checked (no credentials)